Invanz

Ertapenem, the active ingredient in Invanz, is a carbapenem antibiotic presented as an injectable formulation for intravenous use. It is employed to treat serious bacterial infections such as complicated intra‑abdominal infections, skin and soft‑tissue infections, community‑acquired pneumonia, urinary tract infections, and diabetic foot infections in adult patients. GNH USA supplies Invanz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Invanz, a carbapenem antibiotic, is used to treat infections caused by susceptible bacteria in several clinical settings.

Complicated intra‑abdominal infections: effective in managing severe infections of the abdominal cavity. Complicated skin and skin structure infections: helps eradicate resistant skin and soft‑tissue infections. Community‑acquired pneumonia: provides bactericidal activity against common respiratory pathogens. Urinary tract infections: used for serious UTIs caused by susceptible organisms. Diabetic foot infection: aids in controlling deep tissue infections in diabetic patients.

Ertapenem may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Diarrhea: loose stools occurring during or after therapy. - Nausea: feeling of queasiness without vomiting. - Headache: mild to moderate pain in the head region. - Injection site pain: discomfort at the intravenous infusion site. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of rash, swelling, and breathing difficulty. - Clostridioides difficile colitis: severe diarrhea due to intestinal flora disruption. - Seizures: rare neurologic events, especially in patients with renal impairment. - Thrombocytopenia: low platelet count leading to bleeding risk. - Renal dysfunction: worsening kidney function in susceptible individuals.

Before using Invanz, clinicians should consider several safety aspects.

Renal function assessment: adjust dosing in patients with impaired kidney function. Allergy history: avoid in individuals with known hypersensitivity to carbapenems or beta‑lactams. Pregnancy and lactation: use only if the potential benefit outweighs the risk, as safety data are limited. Concurrent antibiotics: monitor for additive toxicity when combined with other nephrotoxic agents. Microbial susceptibility: ensure the infecting organism is susceptible to ertapenem. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ertapenem can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may increase risk of seizures. - Probenecid: can raise ertapenem plasma concentrations, leading to toxicity. - Carbapenem‑inducing agents: concurrent use may reduce effectiveness of oral contraceptives.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxic potential requires renal function monitoring. - Loop diuretics: may enhance ototoxicity when used together. - Warfarin: monitor INR as ertapenem may alter anticoagulant effect.